R. Sidhu

发表

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Chromothripsis in Uterine Leiomyomas

J. Douillard, A. Rong, R. Sidhu, 2013 .

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

D. Cunningham, B. Karaszewska, M. Tejani, 2015 .

RAS mutations in colorectal cancer.

J. Douillard, A. Rong, R. Sidhu, 2013, The New England journal of medicine.

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

ASPECCT: panitumumab versus cetuximab for colorectal cancer--authors' reply.

P. Ruff, M. Peeters, T. Price, 2014, The Lancet. Oncology.

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).

Y. Humblet, S. Patterson, M. Peeters, 2013 .

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Marc Peeters, Tae Won Kim, P. Ruff, 2014, The Lancet. Oncology.

2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

A. Bardelli, J. Tabernero, M. Boedigheimer, 2015 .

Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

C. Atreya, M. Ducreux, J. Schellens, 2015 .

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

S. Jaeger, C. Atreya, M. Ducreux, 2016 .

O-0011FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY

Tae Won Kim, P. Ruff, M. Boedigheimer, 2014 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

D. Cunningham, B. Karaszewska, M. Tejani, 2017, The Lancet. Oncology.

Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

Tae Won Kim, P. Ruff, M. Boedigheimer, 2015 .

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

T. Reiman, Sunita Ghosh, L. Pilarski, 2011, Leukemia research.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

J. Hecht, A. Grothey, S. Kopetz, 2015, Cancer treatment reviews.

Outcomes after balloon dilation of congenital aortic stenosis in children and adolescents

B. McCrindle, L. Benson, R. Freedom, 2004, Cardiology in the Young.

Mismatch repair protein MutL becomes limiting during stationary-phase mutation.

R. S. Harris, M. Winkler, S. Rosenberg, 1997, Genes & development.

Mismatch repair is diminished during stationary-phase mutation.

R. S. Harris, M. Winkler, S. Rosenberg, 1999, Mutation research.

Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs

L. Greller, H. Feilotter, R. Somogyi, 2008, Clinical Cancer Research.

Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

J. Jassem, J. Canon, Y. Humblet, 2014 .

Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials

A. Rong, R. Sidhu, S. Dahlberg, 2013, Clinical Cancer Research.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

PD-0004THE PRIME STUDY: SURVIVAL OUTCOMES IN PATIENTS WITH KRAS/NRAS WILD-TYPE METASTATIC COLORECTAL CANCER AND NON-LIVER-LIMITED DISEASE

J. Tabernero, J. Douillard, R. Sidhu, 2014 .

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

MC13-0022 Resection rates and survival in patients with wild-type KRAS/NRAS metastatic colorectal cancer and liver metastases: Data from the PRIME study

J. Tabernero, S. Braun, J. Douillard, 2013 .

Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012 .

Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).

J. Tabernero, Y. Humblet, D. Cunningham, 2012, Journal of Clinical Oncology.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tae Won Kim, P. Ruff, M. Peeters, 2014, The Lancet. Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

F. Lordick, M. Ducreux, Y. Hotko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.